The 'Research Safety Net' Saving Scientists from Funding Crisis
In this episode, Mike Garrett, CEO of Taconic Biosciences, discusses how preclinical research companies are helping drug developers navigate the current challenging funding environment. He explains that investors now demand more robust translational data showing real potential to impact human health, rather than just basic in vitro results, forcing researchers to generate better evidence packages earlier in development.
This episode is presented in partnership with Taconic Biosciences.
Host
Lori Ellis, Head of Insights, BioSpace
Guest
Mike Garret, CEO, Taconic Biosciences…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.